We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Zinc and Copper Buildup May Cause Alzheimer's Disease

By Biotechdaily staff writers
Posted on 16 Jan 2004
By showing that a metal-protein attenuating compound (MPAC) can inhibit zinc and copper ions from binding to beta amyloid in a clinical trial and thereby treat Alzheimer's disease, a Harvard researcher has been able to provide support for his theory that chemicals are the cause of the disease. More...
The results of the trial were reported in he December 12, 2003, issue of the Archives of Neurology.

In the view of Dr. Ashley Bush, of Harvard Medical School (Boston, MA, USA), Alzheimer's disease is caused by a copper and zinc buildup in the brain. In experiments, he found that by adding zinc to dead brain tissue, the beta amyloid would form clumps resembling the plaques of Alzheimer's disease. He believes that accumulated copper and zinc mix with beta amyloid in the brains of Alzheimer's patients and oxidize, thereby destroying nerve cells. However, he has had difficulty proving this.

Following a successful mouse study that showed a 50% reduction in amyloid deposits, a small clinical trial of a drug designed to inhibit this process has shown promise as a treatment for Alzheimer's, lending credence to Dr. Bush's theory. In this trial of 32 volunteers, half received a seventy-year-old drug called clioquinol and half received placebo. Those on placebo showed a worsening of Alzheimer's, while those on the drug showed minimal deterioration. Additionally, those taking the drug had a decline of amyloid protein in their blood levels, which did not occur in those on placebo. A number of scientists are now pushing for further research on this drug or similar drugs, and large-scale clinical trials are in the planning stage at two universities.




Related Links:
Harvard Medical

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
D-Dimer Test
Epithod 616 D-Dimer Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.